XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS' EQUITY
 6 Months Ended
Jun. 30, 2024
STOCKHOLDERS' EQUITY [Abstract]  
STOCKHOLDERS' EQUITY
8.
STOCKHOLDERS’ EQUITY

Preferred Stock

The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par value per share. There were no shares of preferred stock outstanding at June 30, 2024 and December 31, 2023.
Common Stock

As of June 30, 2024 and December 31, 2023, the Company was authorized to issue 300,000,000 shares of its common stock, $0.0001 par value per share, and 233,026,736 and 226,063,032 shares of common stock were outstanding as of June 30, 2024 and December 31, 2023, respectively. After giving effect to the 31,407,217 shares reserved for outstanding warrants and awards issued or reserved for future issuance under the Company’s equity incentive plans, as of June 30, 2024 there were 35,566,047 shares of common stock available for issuance.

Warrants

 

On January 10, 2024, a former noteholder of the Company exercised a warrant to purchase 4 million shares of the Company’s common stock on a cashless basis and the Company issued 1,977,514 shares of common stock to this noteholder. On March 8, 2024 Hayfin and its affiliates exercised warrants to purchase an aggregate of 3,388,681 shares of the Company’s common stock on a cashless basis and the Company issued 2,482,205 shares of common stock to Hayfin and its affiliates. On March 14, 2024 an entity associated with another former noteholder of the Company exercised a warrant to purchase 169,651 shares of the Company’s common stock on a cashless basis and the Company issued 85,784 shares of common stock to this entity. On May 9, 2024 Hayfin and its affiliates exercised warrants to purchase an aggregate of 1,787,424 shares of the Company’s common stock on a cashless basis and the Company issued 937,507 shares of common stock to Hayfin and its affiliates.

On February 24, 2024 a warrant to purchase 34,800 shares of the Company’s common stock held by a former noteholder of the Company expired in accordance with its terms. At June 30, 2024 and December 31, 2023, the Company had outstanding warrants to purchase an aggregate of 3,122,350 and 12,502,906 shares, respectively, of common stock, with weighted-average exercise prices of $2.08 and $2.32 per share, respectively, with expiration dates ranging between October 2024 and May 2030. The following table summarizes information about warrants outstanding for the six months ended June 30, 2024:

   
Shares
    
Weighted
Average
Exercise Price
  
Warrants outstanding at December 31, 2023
    
12,502,906
 
$
2.32
  
Expired
    
(34,800
)
  
$
7.50
  
Granted
    
-
 
$
-
  
Exercised
    
(9,345,756
)
  
$
2.38
  
Warrants outstanding at June 30, 2024
    
3,122,350
 
$
2.08
  


Equity Incentive Plans

The fair value of stock options granted under the Company’s equity incentive plans was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2024 and 2023:
   
Six Months Ended June 30,
  
   
2024
    
2023
  
Expected term
  
5.5 - 6.3 years
    
5.5 - 6.3 years
  
Volatility
  
66%
 
68%

Dividend yield
  
0.0
    
0.0
  
Risk-free interest rate
  
4.29-4.34%

 
4.20-4.24%



 During the six months ended June 30, 2024 and 2023, the Company granted options to purchase an aggregate of 1,396,524 and 1,727,510 shares of common stock, respectively, to its directors and employees.  The weighted average remaining contractual life of stock options outstanding and expected to vest at June 30, 2024 is 7.3 years.  The weighted average remaining contractual life of stock options exercisable at June 30, 2024 is 6.0 years.  During the six months ended June 30, 2024, options to purchase an aggregate of 555,171 shares of common stock were exercised, which included certain exercise transactions for which an aggregate of 20,774 shares were withheld to cover the exercise price, and the Company received aggregate net exercise proceeds of $1.4 million.




A summary of the Company’s option activity under the Company’s equity incentive plans and related information is as follows:

   
Shares
    
Weighted
Average
Exercise Price
  
Options outstanding, vested and expected to vest at December 31, 2023
    
5,906,184
    
$
3.38
  
Forfeited
    
(15,702
)
  
$
1.94
  
Expired
    
(212,717
)
  
$
7.55
  
Granted
    
1,396,524
    
$
5.65
  
Exercised     (555,171 )   $ 2.76  
Options outstanding, vested and expected to vest at June 30, 2024
    
6,519,118
    
$
3.79
  
                 
Options exercisable
    
3,585,489
    
$
3.55
  


As of June 30, 2024, the Company had $7.3 million of unrecognized compensation expense related to options granted under the Company’s equity incentive plans, which is expected to be recognized over a weighted-average period of 2.9 years.

During the six months ended June 30, 2024 and 2023, the Company granted RSUs representing an aggregate of 2,781,288 and 2,976,260 shares, respectively, to certain employees of the Company and to members of its Board of Directors. These RSUs generally vest annually over a period of four years for employees and semi-annually over a period of one year for directors. During the six months ended June 30, 2024, an aggregate of 1,386,350 shares of common stock vested in connection with grants of RSUs. With respect to these vested RSUs, 440,053 shares valued at approximately $3.2 million were withheld by the Company to cover employees’ tax liabilities. These shares were no longer outstanding as of June 30, 2024. A summary of the Company’s unvested RSU activity and related information is as follows:

   
Shares
    
Weighted
Average Grant
Date Fair Value
  
Balance at December 31, 2023
    
4,657,297
    
$
2.81
  
Granted
    
2,781,288
    
$
5.61
  
Vested
    
(1,386,350
)
  
$
2.52
  
Forfeited
    
(186,438
)
  
$
3.45
  
Balance at June 30, 2024
    
5,865,797
    
$
4.19
  


As of June 30, 2024, the Company had $21.9 million of unrecognized compensation expense related to unvested RSUs granted under the Company’s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.2 years.

Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the three and six months ended June 30, 2024 and 2023 is as follows:
   
Three Months Ended June 30,
    
Six Months Ended June 30,
  
(in thousands)  
2024
    
2023
    
2024
    
2023
  
Research and development
  
$
24
    
$
9
    
$
41
    
$
15
  
Plasma center operating expenses
    
48
      
40
      
87
      
63
  
Selling, general and administrative
    
2,405
      
1,410
      
4,246
      
2,388
  
Cost of product revenue
    
386
      
178
      
630
      
281
  
Total stock-based compensation expense
  
$
2,863
    
$
1,637
    
$
5,004
    
$
2,747